Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

ESPEN guidelines on chronic intestinal failure in adults

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Colon polyps in patients with short bowel syndrome before and after teduglutide: Post hoc analysis of the STEPS study series

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Enteral Autonomy and Days Off Parenteral Support With Teduglutide Treatment for Short Bowel Syndrome in the STEPS Trials

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Repeated Metabolic Balance Studies in Patients With Short Bowel Syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Loris Pironi
  • Jann Arends
  • Federico Bozzetti
  • Cristina Cuerda
  • Lyn Gillanders
  • Palle Bekker Jeppesen
  • Francisca Joly
  • Darlene Kelly
  • Simon Lal
  • Michael Staun
  • Kinga Szczepanek
  • André Van Gossum
  • Geert Wanten
  • Stéphane Michel Schneider
  • Home Artificial Nutrition & Chronic Intestinal Failure Special Interest Group of ESPEN
View graph of relations

BACKGROUND & AIMS: Chronic Intestinal Failure (CIF) is the long-lasting reduction of gut function, below the minimum necessary for the absorption of macronutrients and/or water and electrolytes, such that intravenous supplementation is required to maintain health and/or growth. CIF is the rarest organ failure. Home parenteral nutrition (HPN) is the primary treatment for CIF. No guidelines (GLs) have been developed that address the global management of CIF. These GLs have been devised to generate comprehensive recommendations for safe and effective management of adult patients with CIF.

METHODS: The GLs were developed by the Home Artificial Nutrition & Chronic Intestinal Failure Special Interest Group of ESPEN. The GRADE system was used for assigning strength of evidence. Recommendations were discussed, submitted to Delphi rounds, and accepted in an online survey of ESPEN members.

RESULTS: The following topics were addressed: management of HPN; parenteral nutrition formulation; intestinal rehabilitation, medical therapies, and non-transplant surgery, for short bowel syndrome, chronic intestinal pseudo-obstruction, and radiation enteritis; intestinal transplantation; prevention/treatment of CVC-related infection, CVC-related occlusion/thrombosis; intestinal failure-associated liver disease, gallbladder sludge and stones, renal failure and metabolic bone disease. Literature search provided 623 full papers. Only 12% were controlled studies or meta-analyses. A total of 112 recommendations are given: grade of evidence, very low for 51%, low for 39%, moderate for 8%, and high for 2%; strength of recommendation: strong for 63%, weak for 37%.

CONCLUSIONS: CIF management requires complex technologies, multidisciplinary and multiprofessional activity, and expertise to care for both the underlying gastrointestinal disease and to provide HPN support. The rarity of the condition impairs the development of RCTs. As a consequence, most of the recommendations have a low or very low grade of evidence. However, two-thirds of the recommendations are considered strong. Specialized management and organization underpin these recommendations.

Original languageEnglish
JournalClinical nutrition (Edinburgh, Scotland)
Volume35
Issue number2
Pages (from-to)247-307
Number of pages61
ISSN0261-5614
DOIs
Publication statusPublished - Apr 2016

    Research areas

  • Animals, Chronic Disease, Disease Management, Disease Models, Animal, Enteritis, Humans, Intestinal Pseudo-Obstruction, Liver Diseases, Parenteral Nutrition, Home, Practice Guidelines as Topic, Randomized Controlled Trials as Topic, Short Bowel Syndrome, Journal Article, Research Support, Non-U.S. Gov't

ID: 49680856